|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5.
|
22400995 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, our findings provide evidence for the existence of a novel mechanistic link between increased TR and TRAIL levels in HCC.
|
22576662 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that TRAIL induces the hepatocellular carcinoma apoptosis associated with A20 knockdown in a concentration-dependent manner.
|
22285182 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we describe finding the best linker, that is, sequence encoding the four amino acids IETD, to join the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene and the second mitochondria-derived activator of caspase (Smac) gene to form TRAIL-IETD-Smac and inserting it into oncolytic viral vector ZD55 to construct ZD55-TRAIL-IETD-Smac, which matched ZD55-TRAIL plus ZD55-Smac in completely eliminating xenograft hepatoma.
|
22530834 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, as a new therapeutic strategy, the combination of chemotherapeutic agents and TRAIL gene modified MSCs (TRAIL-MSCs) would improve the therapeutic efficacy of HCC in vivo.
|
22922789 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
|
21412282 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Next, effects of Gli2 gene silencing, on cell proliferation and on the expression of cell cycle-related proteins were evaluated, then, whether down-regulation of Gli2 renders HCC cell susceptible to TRAIL was examined in vitro.
|
21695716 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RNA interference-mediated hTERT inhibition enhances TRAIL-induced apoptosis in resistant hepatocellular carcinoma cells.
|
20204286 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The transgene TRAIL expression controlled by hTERT promoter was evaluated in BEL7404 HCC cell line.
|
20213096 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that ATRA or TRAIL resistance in AFP producing hepatoma is at least, in part, attributable to the high level of the cytoplasmic AFP.
|
19267404 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.
|
19106147 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpressing HBc significantly decreased TRAIL-induced apoptosis of human hepatoma cells, whereas knocking-down HBc expression in hepatoma cells transfected with HBV genome enhanced it.
|
18927587 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice.
|
19223770 |
2009 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our results reveal a new mechanism by which caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells.
|
18992712 |
2009 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
|
18485417 |
2008 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Failure to induce apoptosis triggered by members of the death receptor family has been described in hepatocellular carcinoma (HCC) and sensitization of malignant cells to pro-apoptotic molecules such as TRAIL has been proposed as an alternative cancer therapy.
|
17224200 |
2007 |
|
Liver carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
RNA interference and TRAIL receptor blockage experiments revealed that in bortezomib-treated hepatoma cells TRAIL-R1/TRAIL-R2 up-regulation, enhanced TRAIL DISC formation and cFLIPL down-regulation in addition to accumulation of Bak cooperatively sensitized for TRAIL.
|
17326159 |
2007 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined delivery of Ad/hTERT-CYLD and ZD55-TRAIL may be a new useful strategy for HCC or other tumor cells with enhanced NF-kappaB activity.
|
16627981 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated transfection of caspase-8 sensitizes hepatocellular carcinoma to TRAIL- and chemotherapeutic agent-induced cell death.
|
16750275 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is possible that survivin downregulation by siRNA combined with TRAIL administration may provide a new therapeutic strategy against hepatoma.
|
16820920 |
2006 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
|
16082383 |
2006 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
|
16082383 |
2006 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
The combined delivery of Ad/hTERT-CYLD and ZD55-TRAIL may be a new useful strategy for HCC or other tumor cells with enhanced NF-kappaB activity.
|
16627981 |
2006 |